eXoZymes, Inc. (EXOZ)
| Market Cap | 47.37M -43.4% |
| Revenue (ttm) | n/a |
| Net Income | -9.67M |
| EPS | -1.15 |
| Shares Out | 9.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,640 |
| Open | 5.16 |
| Previous Close | 5.11 |
| Day's Range | 5.12 - 5.31 |
| 52-Week Range | 4.35 - 18.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About EXOZ
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Financial Performance
Financial StatementsNews
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded ...
eXoZymes Inc trading halted, volatility trading pause
09:35 EDT eXoZymes (EXOZ) Inc trading halted, volatility trading pause
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new ca...
eXoZymes Inc. Announces Closing of $6 Million Public Offering
LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceutica...
eXoZymes prices 592,270 shares at $18.00 in public offering
eXoZymes (EXOZ) announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant. The Company has sold 592,270…
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutra...
eXoZymes Quarterly report: Q1 2026
eXoZymes has published its Q1 2026 quarterly earnings report on May 14, 2026.
eXoZymes announces graduation from Shell GameChanger Accelerator
eXoZymes (EXOZ) announced its graduation from the Shell GameChanger Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy’s N...
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medici...
eXoZymes Slides: Investor presentation
eXoZymes has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals ...
eXoZymes Slides: Investor presentation
eXoZymes has posted slides in relation to its latest quarterly earnings report, which was published on April 10, 2026.
eXoZymes Slides: Investor presentation
eXoZymes has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
eXoZymes Earnings Call Transcript: Q4 2025
2025 saw a strategic shift to focused asset development, highlighted by NCT's successful scale-up and tech transfer, and a strengthened pipeline in cannabinoids and santalene. Operating expenses rose due to R&D, with cash runway into mid-Q2 2026 and a new financing round underway.
eXoZymes Earnings release: Q4 2025
eXoZymes released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
eXoZymes Annual report: Q4 2025
eXoZymes has published its Q4 2025 annual report on March 31, 2026.
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
Management to Host Conference Call Today at 5:30 PM Eastern LOS ANGELES, CA / ACCESS Newswire / March 31, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that...
eXoZymes Slides: Investor presentation
eXoZymes has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals ...
eXoZymes announces validation milestone for its biomanufacturing platform
eXoZymes (EXOZ) announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes’ technology a...
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals ...
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals ...
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutrace...
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways...